miR-370 regulates cell proliferation and migration by targeting EGFR in gastric cancer Corrigendum in /10.3892/or.2022.8409

Ning,Tao; Zhang,Haiyang; Wang,Xinyi; Li,Shuang; Zhang,Le; Deng,Ting; Zhou,Likun; Liu,Rui; Wang,Xia; Bai,Ming; Ge,Shaohua; Li,Hongli; Huang,Dingzhi; Ying,Guoguang; Ba,Yi

doi:10.3892/or.2017.5660

miR-370 regulates cell proliferation and migration by targeting EGFR in gastric cancer

Corrigendum in: /10.3892/or.2022.8409

Authors:
- Tao Ning
- Haiyang Zhang
- Xinyi Wang
- Shuang Li
- Le Zhang
- Ting Deng
- Likun Zhou
- Rui Liu
- Xia Wang
- Ming Bai
- Shaohua Ge
- Hongli Li
- Dingzhi Huang
- Guoguang Ying
- Yi Ba
View Affiliations

Affiliations: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Cinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: May 23, 2017 https://doi.org/10.3892/or.2017.5660
Pages: 384-392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor (EGFR) is known to be overexpressed in ~30% of gastric cancer (GC) cases, and may serve as an effective biomarker for predicting the clinical benefit of anti-EGFR therapy. However, the mechanism underlying the regulation of EGFR expression remains unknown. Evidence indicates that post-transcriptional regulation may exist in the process of EGFR expression. In the present study, we aimed to explore whether miR-370 is involved in this process, and how it impacts the biological behaviors of GC cells. In the present study, we first determined the role of EGFR in GC by means of an EGFR overexpression plasmid and siRNAs. Then, the expression levels of EGFR protein and mRNA in GC tissues were analyzed through immunohistochemistry and quantitative RT-PCR (RT-qPCR). Bioinformatics tools and dual-luciferase assay were applied to predict and validate the relevant miRNA targeting EGFR. Finally, human GC MGC-803 cells were selected to explore the effect of miRNA on cell proliferation and migration. We found that suppression of EGFR inhibited the proliferation and migration of GC cells. In addition, the levels of EGFR protein in the GC tissues were ~4 times higher than that in the corresponding paired non-cancerous tissues while the mRNA levels of EGFR were only ~2-fold as high as that in the adjacent non-cancerous tissues. Bioinformatics tools predicted that miRNA-370 was a regulator of EGFR and dual‑luciferase assay validated that miR-370 could directly bind to the 3'-untranslated region (3'-UTR) of EGFR mRNA. Meanwhile, an inverse correlation between miR-370 and EGFR was found in the GC tissues. Overexpression of miR-370 suppressed the proliferation and migration of GC cells, while downregulation of miR-370 promoted proliferation and migration. The present study may provide new information for understanding the molecular mechanism underlying the regulation of EGFR protein expression in GC and may be of important clinical significance to guide targeted therapy.

View Figures

View References

1	Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, et al CONCORD Working Group: Global surveillance of cancer survival 1995–2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
2	Dixon M, Mahar AL, Helyer LK, Vasilevska-Ristovska J, Law C and Coburn NG: Prognostic factors in metastatic gastric cancer: Results of a population-based, retrospective cohort study in Ontario. Gastric Cancer. 19:150–159. 2016. View Article : Google Scholar : PubMed/NCBI
3	Strong VE, Wu AW, Selby LV, Gonen M, Hsu M, Song KY, Park CH, Coit DG, Ji JF and Brennan MF: Differences in gastric cancer survival between the U.S. and China. J Surg Oncol. 112:31–37. 2015. View Article : Google Scholar : PubMed/NCBI
4	Xu W, Yang Z and Lu N: Molecular targeted therapy for the treatment of gastric cancer. J Exp Clin Cancer Res. 35:12016. View Article : Google Scholar : PubMed/NCBI
5	Yarden Y and Pines G: The ERBB network: At last, cancer therapy meets systems biology. Nat Rev Cancer. 12:553–563. 2012. View Article : Google Scholar : PubMed/NCBI
6	Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako M: ACTS-GC Group: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yang W, Raufi A and Klempner SJ: Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. Biochim Biophys Acta. 1846:232–237. 2014.PubMed/NCBI
8	Fontana E and Smyth EC: Novel targets in the treatment of advanced gastric cancer: A perspective review. Ther Adv Med Oncol. 8:113–125. 2016. View Article : Google Scholar : PubMed/NCBI
9	Jiang Z, Li C, Li F and Wang X: EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: A systematic review and meta analysis. PLoS One. 8:e562052013. View Article : Google Scholar : PubMed/NCBI
10	Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, De Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
11	Higaki E, Kuwata T, Nagatsuma AK, Nishida Y, Kinoshita T, Aizawa M, Nitta H, Nagino M and Ochiai A: Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: Evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method. Gastric Cancer. 19:63–73. 2016. View Article : Google Scholar : PubMed/NCBI
12	Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology. 52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
13	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
14	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
15	Friedman JM and Jones PA: MicroRNAs: Critical mediators of differentiation, development and disease. Swiss Med Wkly. 139:466–472. 2009.PubMed/NCBI
16	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
17	Li X, Zhang Z, Yu M, Li L, Du G, Xiao W and Yang H: Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci. 14:16226–16239. 2013. View Article : Google Scholar : PubMed/NCBI
18	Li H, Xie S, Liu X, Wu H, Lin X, Gu J, Wang H and Duan Y: Matrine alters microRNA expression profiles in SGC-7901 human gastric cancer cells. Oncol Rep. 32:2118–2126. 2014.PubMed/NCBI
19	Riquelme I, Tapia O, Leal P, Sandoval A, Varga MG, Letelier P, Buchegger K, Bizama C, Espinoza JA, Peek RM, et al: miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol. 39:23–33. 2016. View Article : Google Scholar
20	El-Daly SM, Abba ML, Patil N and Allgayer H: miRs-134 and −370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signaling. Sci Rep. 6:247202016. View Article : Google Scholar : PubMed/NCBI
21	Zeng Y, Fu M, Wu GW, Zhang AZ, Chen JP, Lin HY, Fu YA, Jia J, Cai ZD, Wu XJ, et al: Upregulation of microRNA-370 promotes cell apoptosis and inhibits proliferation by targeting PTEN in human gastric cancer. Int J Oncol. 49:1589–1599. 2016.PubMed/NCBI
22	John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol. 2:e3632004. View Article : Google Scholar : PubMed/NCBI
23	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
24	Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar : PubMed/NCBI
25	Yang S, Luo A, Hao X, Lai Z, Ding T, Ma X, Mayinuer M, Shen W, Wang X, Lu Y, et al: Peroxiredoxin 2 inhibits granulosa cell apoptosis during follicle atresia through the NFKB pathway in mice. Biol Reprod. 84:1182–1189. 2011. View Article : Google Scholar : PubMed/NCBI
26	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
27	Weng X, Zhang H, Ye J, Kan M, Liu F, Wang T, Deng J, Tan Y, He L and Liu Y: Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer. Sci Rep. 5:101542015. View Article : Google Scholar : PubMed/NCBI
28	Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, et al: EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008. View Article : Google Scholar : PubMed/NCBI
29	Uhlmann S, Mannsperger H, Zhang JD, Horvat EA, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, et al: Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 8:5702012. View Article : Google Scholar : PubMed/NCBI
30	Mlcochova J, Faltejskova P, Nemecek R, Svoboda M and Slaby O: MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol. 139:1615–1624. 2013. View Article : Google Scholar : PubMed/NCBI
31	Chen T, Gao F, Feng S, Yang T and Chen M: MicroRNA-370 inhibits the progression of non-small cell lung cancer by downregulating oncogene TRAF4. Oncol Rep. 34:461–468. 2015.PubMed/NCBI
32	Yungang W, Xiaoyu L, Pang T, Wenming L and Pan X: miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC). Biomed Pharmacother. 68:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
33	Meng F, Wehbe-Janek H, Henson R, Smith H and Patel T: Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 27:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
34	Chen XP, Chen YG, Lan JY and Shen ZJ: MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett. 353:201–210. 2014. View Article : Google Scholar : PubMed/NCBI
35	Chang KW, Chu TH, Gong NR, Chiang WF, Yang CC, Liu CJ, Wu CH and Lin SC: miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma. Oral Dis. 19:611–619. 2013. View Article : Google Scholar : PubMed/NCBI
36	Lo SS, Hung PS, Chen JH, Tu HF, Fang WL, Chen CY, Chen WT, Gong NR and Wu CW: Overexpression of miR-370 and downregulation of its novel target TGFβ-RII contribute to the progression of gastric carcinoma. Oncogene. 31:226–237. 2012. View Article : Google Scholar : PubMed/NCBI
37	Fan C, Liu S, Zhao Y, Han Y, Yang L, Tao G, Li Q and Zhang L: Upregulation of miR-370 contributes to the progression of gastric carcinoma via suppression of FOXO1. Biomed Pharmacother. 67:521–526. 2013. View Article : Google Scholar : PubMed/NCBI
38	Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP, Gui QJ, Zhang L and Li GQ: miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 31:1715–1722. 2014.PubMed/NCBI
39	Liu G, Jiang C, Li D, Wang R and Wang W: MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 35:9801–9806. 2014. View Article : Google Scholar : PubMed/NCBI